Contact Us
Global Medications For Heart Failure Market Report 2025

Medications For Heart Failure Global Market Report 2025 - By Drug Class (Angiotensin-Converting Enzyme (ACE) Inhibitors, Beta Blockers, Diuretics, Aldosterone Antagonists, Angiotensin II Receptor Blockers (ARBs), Other Drug Classes), By Route Of Administration (Oral, Intravenous, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels), By Application (Hospital, Clinic, Other Applications) - Market Size, Trends, And Global Forecast 2025-2034

Medications For Heart Failure Global Market Report 2025

Report Price : $4490.00 | Pages : 200 | Published : June 2025 | Delivery Time: 2-3 business days Info icon | Format : pdf icon

Need assistance or more information before the purchase?

Enquire Before Buying
Medications For Heart Failure Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Medications For Heart Failure Market?

Medications for heart failure are drugs used to treat and manage heart failure, a condition in which the heart cannot pump blood effectively to meet the body's needs. These medications help improve heart function, relieve symptoms, prevent hospitalizations, and increase survival.

The main types of drug classes of medications for heart failure are angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, aldosterone antagonists, angiotensin II receptor blockers (ARBs), and others. ACE inhibitors relax blood vessels by blocking the formation of angiotensin II, lowering blood pressure, and reducing the heart's workload, and are commonly used for high blood pressure and heart failure. It is administered through different routes of administration, such as oral, intravenous, and others, and distributed through various distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, for several applications, such as hospitals, clinics, and others.

Medications For Heart Failure Market Size and growth rate 2025 to 2029: Graph

What Is The Medications For Heart Failure Market Size 2025 And Growth Rate?

The medications for the heart failure market size has grown strongly in recent years. It will grow from $10.14 billion in 2024 to $10.90 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to the rising prevalence of cardiovascular diseases, increasing diagnosis and awareness, regulatory approvals and support, increasing R&D spending on cardiovascular drugs, and the adoption of telemedicine and remote monitoring tools.

What Is The Medications For Heart Failure Market Growth Forecast?

The medications for the heart failure market size is expected to see strong growth in the next few years. It will grow to $14.37 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growth in personalized and precision medicine, the rising global burden of lifestyle diseases, the pipeline of combination therapies and fixed-dose formulations, increasing clinical evidence and updated guidelines, and increasing urbanization. Major trends in the forecast period include the growth of SGLT2 inhibitors, digital health integration, remote monitoring tools and AI-driven analytics, increasing focus on HFpEF treatment, and ongoing research and development.

How Is The Medications For Heart Failure Market Segmented?

The medications for heart failure market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, beta blockers, Diuretics, Aldosterone Antagonists, Angiotensin II Receptor Blockers (ARBs), Other Drug Classes

2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril, Captopril, Perindopril, Other Angiotensin-Converting Enzyme (ACE) Inhibitors

2) By Beta Blockers: Carvedilol, Metoprolol Succinate, Bisoprolol, Nebivolol, Other Beta Blockers

3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics, Other Diuretics

4) By Aldosterone Antagonists: Spironolactone, Eplerenone, Other Aldosterone Antagonists

5) By Angiotensin II Receptor Blockers (ARBs): Valsartan, Losartan, Candesartan, Irbesartan, Other Angiotensin II Receptor Blockers (ARBs)

6) By Other Drug Classes: Angiotensin Receptor-Neprilysin Inhibitors, Ivabradine, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Hydralazine Or Isosorbide Dinitrate, Digoxin, Other Medications

What Is Driving The Medications For Heart Failure Market? The Rising Prevalence Of Cardiovascular Diseases Fueling The Growth Of The Market Due To Increasing Demand For Effective Heart Failure Treatments

The rising prevalence of cardiovascular diseases is expected to propel the growth of the medications for the heart failure market going forward. Cardiovascular diseases refer to conditions that impact the heart and blood vessels, commonly resulting in severe issues such as heart attacks and strokes. The rise in cardiovascular diseases is largely driven by sedentary lifestyles that weaken heart and vessel health over time. As cardiovascular disease rates rise, the demand for effective treatments grows, prompting greater investment in heart failure medications. With the condition becoming more widespread, pharmaceutical companies are prioritizing the development and enhancement of therapies to better manage symptoms and improve patient outcomes. For instance, in September 2024, according to the Heart Failure Society of America (HFSA), a US-based organization of heart failure experts, around 6.7 million Americans aged 20 and older currently live with heart failure (HF), with the number projected to increase to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. Therefore, the rising prevalence of cardiovascular diseases is driving the growth of medications for the heart failure market.

Who Are The Major Players In The Global Medications For Heart Failure Market?

Major companies operating in the medications for heart failure market are Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals Inc., Steris Pharma, CSPC Pharmaceutical, Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals, Ionis Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Hainan Poly Pharm. Co. Ltd., Addii Biotech, Lunan Pharmaceutical Group, Mylan Laboratories Inc., Neuracle Lifesciences Private Limited, JM Laboratories, Lexicon Pharmaceuticals.

What Are The Key Trends Of The Global Medications For Heart Failure Market? Advancements In Sodium-Glucose Cotransporter (SGLT) Inhibitors For Heart Failure Management

Major companies operating in the medication for heart failure market are focused on developing advanced drugs, such as sodium-glucose cotransporter (SGLT) inhibitors, to provide more effective long-term management of heart failure symptoms and complications. An SGLT inhibitor is an advanced medication that targets glucose reabsorption mechanisms to manage heart failure, enhance efficiency, and optimize cardiovascular health. For instance, in May 2023, Lexicon Pharmaceuticals, a US-based biopharmaceutical company, introduced Inpefa (sotagliflozin), which received approval from the Food and Drug Administration (FDA). It is a once-daily oral tablet designed to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. This approval marks a significant milestone for Lexicon, as Inpefa is the first dual SGLT1/SGLT2 inhibitor to reach the market, offering a new treatment option for heart failure patients across a broad range of conditions.

What Are Latest Mergers And Acquisitions In The Medications For Heart Failure Market? Novo Nordisk Acquired Cardior Pharmaceuticals To Bolster Heart Failure Drug Pipeline

In March 2024, Novo Nordisk, a Denmark-based pharmaceutical company, acquired Cardior Pharmaceuticals for $1.112 billion. The acquisition aims to strengthen Novo Nordisk's pipeline in cardiovascular disease, particularly with Cardior's lead compound CDR132L, which is in phase 2 clinical development for treating heart failure. Cardior Pharmaceuticals is a Germany-based biotechnology company that is involved in the research of oligonucleotide-based inhibitors designed for heart failure.

What Is The Regional Outlook For The Global Medications For Heart Failure Market?

North America was the largest region in the medications for the heart failure market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medications for heart failure market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the medications for heart failure market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Medications For Heart Failure Market?

The medications for the heart failure market consist of sales of angiotensin receptor-neprilysin inhibitors, hydralazine and nitrates, ivabradine, and digoxin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Medications For Heart Failure Industry?

The medications for heart failure market research report is one of a series of new reports from The Business Research Company that provides medications for heart failure market statistics, including the medications for heart failure industry global market size, regional shares, competitors with the medications for heart failure market share, detailed medications for heart failure market segments, market trends, and opportunities, and any further data you may need to thrive in the medications for heart failure industry. This medications for heart failure market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Medications For Heart Failure Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $10.90 billion
Revenue Forecast In 2034 $14.37 billion
Growth Rate CAGR of 7.2% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The medications for heart failure market covered in this report is segmented –
1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Beta Blockers, Diuretics, Aldosterone Antagonists, Angiotensin II Receptor Blockers (ARBs), Other Drug Classes
2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By Application: Hospital, Clinic, Other Applications Subsegments:
1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril, Captopril, Perindopril, Other Angiotensin-Converting Enzyme (ACE) Inhibitors
2) By Beta Blockers: Carvedilol, Metoprolol Succinate, Bisoprolol, Nebivolol, Other Beta Blockers
3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics, Other Diuretics
4) By Aldosterone Antagonists: Spironolactone, Eplerenone, Other Aldosterone Antagonists
5) By Angiotensin II Receptor Blockers (ARBs): Valsartan, Losartan, Candesartan, Irbesartan, Other Angiotensin II Receptor Blockers (ARBs)
6) By Other Drug Classes: Angiotensin Receptor-Neprilysin Inhibitors, Ivabradine, Sodium-Glucose Cotransporter-2 (SGLT
2) Inhibitors, Hydralazine Or Isosorbide Dinitrate, Digoxin, Other Medications
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals Inc., Steris Pharma, CSPC Pharmaceutical, Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals, Ionis Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Hainan Poly Pharm. Co. Ltd., Addii Biotech, Lunan Pharmaceutical Group, Mylan Laboratories Inc., Neuracle Lifesciences Private Limited, JM Laboratories, Lexicon Pharmaceuticals.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Medications For Heart Failure Market Characteristics

    3. Medications For Heart Failure Market Trends And Strategies

    4. Medications For Heart Failure Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

    5. Global Medications For Heart Failure Growth Analysis And Strategic Analysis Framework

    5.1. Global Medications For Heart Failure PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Medications For Heart Failure Market Growth Rate Analysis

    5.4. Global Medications For Heart Failure Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Medications For Heart Failure Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Medications For Heart Failure Total Addressable Market (TAM)

    6. Medications For Heart Failure Market Segmentation

    6.1. Global Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Angiotensin-Converting Enzyme (ACE) Inhibitors

    Beta Blockers

    Diuretics

    Aldosterone Antagonists

    Angiotensin II Receptor Blockers (Arbs)

    Other Drug Classes

    6.2. Global Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Oral

    Intravenous

    Other Routes Of Administration

    6.3. Global Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Online Pharmacies

    Other Distribution Channels

    6.4. Global Medications For Heart Failure Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospital

    Clinic

    Other Applications

    6.5. Global Medications For Heart Failure Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Enalapril

    Lisinopril

    Ramipril

    Captopril

    Perindopril

    Other Angiotensin-Converting Enzyme (ACE) Inhibitors

    6.6. Global Medications For Heart Failure Market, Sub-Segmentation Of Beta Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Carvedilol

    Metoprolol Succinate

    Bisoprolol

    Nebivolol

    Other Beta Blockers

    6.7. Global Medications For Heart Failure Market, Sub-Segmentation Of Diuretics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Loop Diuretics

    Thiazide Diuretics

    Potassium-Sparing Diuretics

    Other Diuretics

    6.8. Global Medications For Heart Failure Market, Sub-Segmentation Of Aldosterone Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Spironolactone

    Eplerenone

    Other Aldosterone Antagonists

    6.9. Global Medications For Heart Failure Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Valsartan

    Losartan

    Candesartan

    Irbesartan

    Other Angiotensin II Receptor Blockers (ARBs)

    6.10. Global Medications For Heart Failure Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Angiotensin Receptor-Neprilysin Inhibitors

    Ivabradine

    Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

    Hydralazine Or Isosorbide Dinitrate

    Digoxin

    Other Medications

    7. Medications For Heart Failure Market Regional And Country Analysis

    7.1. Global Medications For Heart Failure Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Medications For Heart Failure Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Medications For Heart Failure Market

    8.1. Asia-Pacific Medications For Heart Failure Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Medications For Heart Failure Market

    9.1. China Medications For Heart Failure Market Overview

    9.2. China Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Medications For Heart Failure Market

    10.1. India Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Medications For Heart Failure Market

    11.1. Japan Medications For Heart Failure Market Overview

    11.2. Japan Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Medications For Heart Failure Market

    12.1. Australia Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Medications For Heart Failure Market

    13.1. Indonesia Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Medications For Heart Failure Market

    14.1. South Korea Medications For Heart Failure Market Overview

    14.2. South Korea Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Medications For Heart Failure Market

    15.1. Western Europe Medications For Heart Failure Market Overview

    15.2. Western Europe Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Medications For Heart Failure Market

    16.1. UK Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Medications For Heart Failure Market

    17.1. Germany Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Medications For Heart Failure Market

    18.1. France Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Medications For Heart Failure Market

    19.1. Italy Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Medications For Heart Failure Market

    20.1. Spain Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Medications For Heart Failure Market

    21.1. Eastern Europe Medications For Heart Failure Market Overview

    21.2. Eastern Europe Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Medications For Heart Failure Market

    22.1. Russia Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Medications For Heart Failure Market

    23.1. North America Medications For Heart Failure Market Overview

    23.2. North America Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Medications For Heart Failure Market

    24.1. USA Medications For Heart Failure Market Overview

    24.2. USA Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Medications For Heart Failure Market

    25.1. Canada Medications For Heart Failure Market Overview

    25.2. Canada Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Medications For Heart Failure Market

    26.1. South America Medications For Heart Failure Market Overview

    26.2. South America Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Medications For Heart Failure Market

    27.1. Brazil Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Medications For Heart Failure Market

    28.1. Middle East Medications For Heart Failure Market Overview

    28.2. Middle East Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Medications For Heart Failure Market

    29.1. Africa Medications For Heart Failure Market Overview

    29.2. Africa Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Medications For Heart Failure Market Competitive Landscape And Company Profiles

    30.1. Medications For Heart Failure Market Competitive Landscape

    30.2. Medications For Heart Failure Market Company Profiles

    30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

    31. Medications For Heart Failure Market Other Major And Innovative Companies

    31.1. Novartis AG

    31.2. Eli Lilly and Company

    31.3. Boehringer Ingelheim Pharmaceuticals Inc.

    31.4. Steris Pharma

    31.5. CSPC Pharmaceutical

    31.6. Hikma Pharmaceuticals PLC

    31.7. Cadila Pharmaceuticals

    31.8. Ionis Pharmaceuticals Inc.

    31.9. Valeant Pharmaceuticals International Inc.

    31.10. Hainan Poly Pharm. Co. Ltd.

    31.11. Addii Biotech

    31.12. Lunan Pharmaceutical Group

    31.13. Mylan Laboratories Inc.

    31.14. Neuracle Lifesciences Private Limited

    31.15. JM Laboratories

    32. Global Medications For Heart Failure Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Medications For Heart Failure Market

    34. Recent Developments In The Medications For Heart Failure Market

    35. Medications For Heart Failure Market High Potential Countries, Segments and Strategies

    35.1 Medications For Heart Failure Market In 2029 - Countries Offering Most New Opportunities

    35.2 Medications For Heart Failure Market In 2029 - Segments Offering Most New Opportunities

    35.3 Medications For Heart Failure Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Medications For Heart Failure Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Medications For Heart Failure Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Medications For Heart Failure Market, Sub-Segmentation Of Beta Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Medications For Heart Failure Market, Sub-Segmentation Of Diuretics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Medications For Heart Failure Market, Sub-Segmentation Of Aldosterone Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Medications For Heart Failure Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Medications For Heart Failure Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Medications For Heart Failure Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Medications For Heart Failure Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Asia-Pacific, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: China, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: India, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Japan, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Australia, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Indonesia, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: South Korea, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Western Europe, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: UK, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Germany, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: France, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Italy, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Spain, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Eastern Europe, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Russia, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: North America, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: USA, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Canada, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: South America, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Brazil, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Middle East, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Africa, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: Merck & Co. Inc. Financial Performance
  • Table 82: Bayer AG Financial Performance
  • Table 83: Sanofi SA Financial Performance
  • Table 84: Bristol-Myers Squibb Financial Performance
  • Table 85: AstraZeneca plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Medications For Heart Failure Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Medications For Heart Failure Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Medications For Heart Failure Market, Sub-Segmentation Of Beta Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Medications For Heart Failure Market, Sub-Segmentation Of Diuretics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Medications For Heart Failure Market, Sub-Segmentation Of Aldosterone Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Medications For Heart Failure Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Medications For Heart Failure Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Medications For Heart Failure Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Medications For Heart Failure Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Asia-Pacific, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: China, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: India, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Japan, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Australia, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Indonesia, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: South Korea, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Western Europe, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: UK, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Germany, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: France, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Italy, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Spain, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Eastern Europe, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Russia, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: North America, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: USA, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Canada, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: South America, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Brazil, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Middle East, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Africa, Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: Merck & Co. Inc. Financial Performance
  • Figure 82: Bayer AG Financial Performance
  • Figure 83: Sanofi SA Financial Performance
  • Figure 84: Bristol-Myers Squibb Financial Performance
  • Figure 85: AstraZeneca plc Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the Medications For Heart Failure market?

Medications for heart failure are drugs used to treat and manage heart failure, a condition in which the heart cannot pump blood effectively to meet the body's needs. These medications help improve heart function, relieve symptoms, prevent hospitalizations, and increase survival. For further insights on the Medications For Heart Failure market, request a sample here

How will the Medications For Heart Failure market drivers and restraints affect the market dynamics? What forces will shape the Medications For Heart Failure industry going forward?

The Medications For Heart Failure market major growth driver - The Rising Prevalence Of Cardiovascular Diseases Fueling The Growth Of The Market Due To Increasing Demand For Effective Heart Failure Treatments. For further insights on the Medications For Heart Failure market, request a sample here

What is the forecast market size or the forecast market value of the Medications For Heart Failure market?

The Medications For Heart Failure market size has grown strongly in recent years. The medications for the heart failure market size has grown strongly in recent years. It will grow from $10.14 billion in 2024 to $10.90 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to the rising prevalence of cardiovascular diseases, increasing diagnosis and awareness, regulatory approvals and support, increasing R&D spending on cardiovascular drugs, and the adoption of telemedicine and remote monitoring tools. The medications for the heart failure market size is expected to see strong growth in the next few years. It will grow to $14.37 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growth in personalized and precision medicine, the rising global burden of lifestyle diseases, the pipeline of combination therapies and fixed-dose formulations, increasing clinical evidence and updated guidelines, and increasing urbanization. Major trends in the forecast period include the growth of SGLT2 inhibitors, digital health integration, remote monitoring tools and AI-driven analytics, increasing focus on HFpEF treatment, and ongoing research and development. For further insights on the Medications For Heart Failure market, request a sample here

How is the Medications For Heart Failure market segmented?

The medications for heart failure market covered in this report is segmented –
1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Beta Blockers, Diuretics, Aldosterone Antagonists, Angiotensin II Receptor Blockers (ARBs), Other Drug Classes
2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By Application: Hospital, Clinic, Other Applications
Subsegments:
1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril, Captopril, Perindopril, Other Angiotensin-Converting Enzyme (ACE) Inhibitors
2) By Beta Blockers: Carvedilol, Metoprolol Succinate, Bisoprolol, Nebivolol, Other Beta Blockers
3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics, Other Diuretics
4) By Aldosterone Antagonists: Spironolactone, Eplerenone, Other Aldosterone Antagonists
5) By Angiotensin II Receptor Blockers (ARBs): Valsartan, Losartan, Candesartan, Irbesartan, Other Angiotensin II Receptor Blockers (ARBs)
6) By Other Drug Classes: Angiotensin Receptor-Neprilysin Inhibitors, Ivabradine, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Hydralazine Or Isosorbide Dinitrate, Digoxin, Other Medications For further insights on the Medications For Heart Failure market,
request a sample here

Which region has the largest share of the Medications For Heart Failure market? What are the other regions covered in the report?

North America was the largest region in the medications for the heart failure market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medications for heart failure market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Medications For Heart Failure market, request a sample here.

Who are the major players in the Medications For Heart Failure market?

Major companies operating in the medications for heart failure market are Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals Inc., Steris Pharma, CSPC Pharmaceutical, Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals, Ionis Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Hainan Poly Pharm. Co. Ltd., Addii Biotech, Lunan Pharmaceutical Group, Mylan Laboratories Inc., Neuracle Lifesciences Private Limited, JM Laboratories, Lexicon Pharmaceuticals. . For further insights on the Medications For Heart Failure market, request a sample here.

What are the key trends in the Medications For Heart Failure market?

Major trends in the Medications For Heart Failure market include Advancements In Sodium-Glucose Cotransporter (SGLT) Inhibitors For Heart Failure Management. For further insights on the Medications For Heart Failure market, request a sample here.

What are the major opportunities in the Medications For Heart Failure market? What are the strategies for the Medications For Heart Failure market?

For detailed insights on the major opportunities and strategies in the Medications For Heart Failure market, request a sample here.

How does the Medications For Heart Failure market relate to the overall economy and other similar markets?

For detailed insights on Medications For Heart Failure's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Medications For Heart Failure industry?

For detailed insights on the mergers and acquisitions in the Medications For Heart Failure industry, request a sample here.

What are the key dynamics influencing the Medications For Heart Failure market growth? SWOT analysis of the Medications For Heart Failure market.

For detailed insights on the key dynamics influencing the Medications For Heart Failure market growth and SWOT analysis of the Medications For Heart Failure industry, request a sample here.

Back to top
Back to top